In the EU a rare disease is defined as one with a prevalence of 1 in 2,000 people, and in the US, as affecting fewer than 200,000 people (equivalent to 1 in 1,600 people as of 2013 population figures).
In this report, we will focus on rare diseases defined as per above. By these definitions, there are between 6,000 and 8,000 recognised rare diseases, most of them arising from genetic origin and being chronic or life-threatening.
With the ‘blockbuster bubble’ seemingly burst and patent protection giving way to huge rises in generic competition, the pharma industry appears to be focusing on high value drugs for rare diseases of low prevalence for which there is a potential for rich return on investment.
Using Citeline data, this paper analyzes the landscape for rare diseases and the density of development by phase, developing company and disease.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: